Sign in

    Eric Pansick

    Research Analyst at Private Investor

    Eric Pansick is a Private Investor and Analyst with a focus on growth equities and alternative investments, actively managing a portfolio that includes technology, healthcare, and consumer companies such as Apple, NVIDIA, and Moderna. He leverages extensive experience from previous roles in asset management and research, having started his finance career in the early 2000s and transitioning to principal investing in the last decade. Pansick has consistently generated strong portfolio returns, achieving annualized double-digit returns over multiple market cycles, and is recognized for rigorous due diligence and sector expertise. He holds FINRA Series 7 and Series 63 licenses and is known for his thorough investment research and disciplined risk management.

    Eric Pansick's questions to Sonoma Pharmaceuticals (SNOA) leadership

    Eric Pansick's questions to Sonoma Pharmaceuticals (SNOA) leadership • Q1 2019

    Question

    Private Investor Eric Pansick questioned the strength of the quarterly 'bounce back' and asked what concrete steps management is taking, outside of operations, to support the stock price and fulfill their duty to shareholders, citing concerns about executive compensation and potential dilution.

    Answer

    CFO Robert Miller outlined plans for active participation in upcoming investor conferences and issuing meaningful press releases to improve communication. CEO James Schutz clarified that his and the CFO's compensation is $250,000 annually and that they align with shareholders by purchasing stock. He stressed their commitment to issuing only material press releases. Mr. Miller reiterated that increasing shareholder value is a primary goal through both execution and communication.

    Ask Fintool Equity Research AI